Citations

Clear

1526 citation(s) found for "Sun, Yu".

Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases
Butensky, Samuel D. , Bansal, Varun , Su, David , Waheed, Muhammad Talha , Nikiforchin, Andrei , Gomez‐Mayorga, Jorge L. , Radomski, Shannon N. , Sun, Beatrice J. , Turaga, Kiran K. , Gunderson, Craig G. , Lacy, Jill , In, Haejin, Kennedy, Timothy J., Yoon, Harry H. , Sundar, Raghav , Ly, Quan P. , Fackche, Nadege , Chan, Carlos H.F. , Maron, Steven B. , Hoehn, Richard S. , Bansal, Varun V , Su, David G , Radomski, Shannon N , Turaga, Kiran K , Badgwell, Brian D , Yoon, Harry H , Chan, Carlos H F , Hoehn, Richard , Olecki, Elizabeth Josephine , Badgwell, Brian D. , In, Haejin , Greer, Jonathan B. , Woo, Yanghee

Mayo Clinic

Cancer | June 25, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35870 | PMID 40558029 Get It

AbstractBackgroundGastric cancer with synchronous peritoneal metastases is a debilitating disease with limited treatment options. This article describes an update of the 2018 Chicago Consensus guidelines addressing the management of gastric cancer with synchronous peritoneal metastases in line with the most recent evidence.MethodsA clinical management pathway was updated through two rounds of a Delphi consensus to assess agreement levels with pathway blocks. Supporting evidence underwent evaluation using a rapid literature review. Meta‐analyses were performed as appropriate.ResultsOverall, the level of evidence in this disease subset was low to moderate. Of 124 participants in the first round, 109 (88%) responded in the second round. Strong consensus (>90%) was achieved in six of eight blocks (75%) in rounds 1 and 2. A multidisciplinary preoperative assessment and diagnostic laparoscopy should be offered to all patients, whereas patients with a high burden of disease or progression should undergo nonsurgical management. Patients with stable/responsive disease and a low peritoneal carcinomatosis index should subsequently be offered treatment with regional therapeutic interventions and cytoreductive surgery. In patients who are cytology‐positive, systemic therapy can be used to convert them to cytology‐negative, with subsequent surgery offered according to the patient's goals of care. Meta‐analysis of observational and randomized control trials revealed a survival benefit with the addition of intraperitoneal chemotherapy to cytoreductive surgery (hazard ratio, 0.52).ConclusionsThe consensus‐driven clinical pathway for gastric cancer with synchronous peritoneal metastases offers vital clinical guidance for practitioners. There is a growing body of high‐quality evidence to support management strategies, and future clinical trials are eagerly awaited.
Abstract Th0038: Endothelial CD40 Drives EndMT-Induced Inflammation In Atherosclerosis
Dzobo, Kim E. , Shami, Annelie , Nardi, Valentina , Xiong, Yuning, Edsfeldt, Andreas , Lutgens, Esther, Nardi, Valentina , Nardi, Valentina , Nitz, Katrin , Sun, Jiangming , Gialeli, Chrysostomi , Barghouth, Mohammad , Lerman, Amir , Wang, Ying , Gonçalves, Isabel , Simons, Michael , Lutgens, Esther

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 23, 2025 | Volume: 45 | Issue: Suppl_1 | Pages: No page available

10.1161/atv.45.suppl_1.th0038 Get It

Introduction: Atherosclerosis, the underlying cause of cardiovascular disease (CVD), is a lipid-driven chronic inflammatory disease. We have identified the co-stimulatory CD40-CD40L immune checkpoint dyad as a key driver of inflammation during atherosclerosis. CD40 and CD40L exert cell-type divergent functions via different signaling pathways. Hypothesis: We hypothesize that CD40 on endothelial cell (ECs) induces endothelial-to-mesenchymal transition (EndMT)-mediated vascular inflammation in atherosclerosis. Methods & Results: Using single cell RNAseq, we found that CD40 (TNFRSF5) is expressed on PDE3A + GJA5 + and KDR + COL15A1 + ECs of advanced human carotid atherosclerotic plaques. CD40 is highly expressed in the endothelial lining of human and mouse atherosclerotic plaques, and colocalizes with the EndMT markers fibronectin and collagen and adhesion molecule ICAM-1. CD40L activation of human aortic endothelial cells (HAECs) results in expression of the EndMT markers fibronectin, vimentin, sm22α, FSP1 and snail. Activation of CD40 in EC induces filamin A dependent translocation of CD40 into lipid rafts, increases TNF-receptor associated factor (TRAFs) -2, -3 and 6 levels, induces Akt signaling and increases expression of VCAM1 and CCL2. Conclusions: The endothelial cell has been more and more regarded as a cell type that plays a major role in driving inflammation. Our data suggest that the CD40-CD40L axis plays a significant role in EC-mediated inflammation in atherosclerosis by driving EndMT.
557 | EVALUATING UPTAKE OF TARGETED AGENTS BY RACE/ETHNICITY IN PATIENTS RECEIVING FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
Kittai, Adam S. , Hampel, Paul J. , Fu, Qiang , Sun, Steven , Beuge, Derrick van, Maglinte, Gregory A. , Rhodes, Joanna , Wang, X., Seymour, Erlene Kuizon , Barrientos, Jacqueline C.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_557 Get It

611 | TUMOR EVOLUTION AND IMMUNE MICROENVIRONMENT DYNAMICS IN PRIMARY AND RELAPSED MANTLE CELL LYMPHOMA
Wan, Hui , Ren, Weicheng , Yang, Mao , Wasik, Agata M. , Nie, M., Yang, Chuan , Ansell, Steven M., Liu, D. , Sander, Birgitta , Li, Xiangchun , Du, Lei , Campos‐Mata, Leire de , Nie, M., Ye, Xiaojing , Yang, Zhi Ping , Burg, Mirjam van der , Wu, Kui , Pan‐Hammarström, Qiang

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_611 Get It

Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance
Velcheti, Vamsidhar , Sun, Xuezheng , Hanna, Maya , Zimmerman, Nicole M. , Singh, W, Shah, Manasee V. , Zhu, Xinmei , Liao, Anne P., Altan, Mehmet , Liao, Anne

Mayo Clinic

The Oncologist | June 11, 2025 | Volume: 30 | Issue: 8 | Pages: No page available

10.1093/oncolo/oyaf070 | PMID 40853136 Get It

Abstract Background Real-world first-line maintenance (1LM) treatment data are limited for advanced/metastatic non-small cell lung cancer (a/mNSCLC). Materials and Methods In this electronic health record-derived, deidentified database study, eligible patients (≥18 years; diagnosed with stage III/IV non-small cell lung cancer [June 1, 2017-September 30, 2021]) initiated pembrolizumab-based 1LM after 4-6 cycles of first-line (1L) platinum-based chemotherapy-pembrolizumab ± pemetrexed. Study outcomes were real-world time to next treatment or death (rwTTNTD), overall survival (rwOS), and predictors of outcomes. Results Of 1944 patients analyzed (median follow-up, 12.2 months), 51.9% received 1LM pembrolizumab-pemetrexed and 48.1% pembrolizumab monotherapy. Median rwTTNTD and rwOS were 9.2 (95% CI: 8.5-9.8) and 18.7 (95% CI: 17.7-20.3) months, respectively. In multivariable analyses, factors significantly associated with shorter rwTTNTD included 5%-<10% (hazard ratio [HR], 1.34; 95% CI: 1.17-1.54) or ≥10% (HR, 1.69; 95% CI: 1.42-2.01) weight loss during 1L versus 0% or <5% weight loss. Programmed death-ligand 1 (PD-L1) expression 1%–49% (HR, 0.81; 95% CI: 0.71-0.93) or ≥50% (HR, 0.55; 95% CI: 0.47-0.64) and female sex (HR, 0.85; 95% CI: 0.75-0.95) were significantly associated with longer rwTTNTD. These variables were also significantly associated with shorter (weight loss 5%-<10%: HR, 1.52; 95% CI: 1.30-1.77; ≥10% HR, 2.06; 95% CI: 1.71-2.48) and longer rwOS (PD-L1 expression: 1%-49% HR, 0.84; 95% CI: 0.72-0.98; ≥ 50% HR, 0.57; 95% CI: 0.48-0.68; female sex: HR, 0.81; 95% CI: 0.71-0.92). Conclusions Predictors of real-world clinical outcomes included 1L treatment, weight loss, PD-L1 status, and sex. Poor outcomes persisted despite immunotherapy-based 1LM availability, revealing an unmet need in this population.
l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells
Ma, Xiaokun , Li, Yin , Huang, Yuebo , Sun, Yuxiang , Sha, Zixin , Lin, Hongchun, Shang, Hongli, Wu, Peizhi, Li, Canming , Ye, Zengchun , Peng, Hui , Peng, Hui , Li, Yongjie, Wei, Dandan, Hu, Cheng , Hu, Zhaoyong

Mayo Clinic

The FASEB Journal | June 11, 2025 | Volume: 39 | Issue: 11 | Pages: No page available

10.1096/fj.202500229r | PMID 40497367 Get It

ABSTRACT Peritoneal fibrosis is one of the main causes of peritoneal dysfunction and withdrawal of patients from peritoneal dialysis (PD). Our previous study has shown that high‐glucose dialysis solution promotes glycolysis in peritoneal mesothelial cells, leading to mesothelial‐to‐mesenchymal transition (MMT) and peritoneal fibrosis. However, the molecular mechanisms remain unclear. Using single‐cell RNA sequencing (scRNA‐seq) analysis of cells from the effluent of patients undergoing PD from our previous study, we found that pyruvate kinase isozymes M2 (PKM2), a key rate‐limiting enzyme of glucose metabolism, was significantly upregulated in the mesothelial cells of patients with long‐term peritoneal dialysis (LPD). Using co‐immunoprecipitation, chromatin immunoprecipitation assay, and gene silencing techniques, we revealed that PKM2 promotes the expression of transcription factor SNAI2 by acetylating histone H3K9 (H3K9ac), thereby promoting the occurrence of MMT and hence peritoneal fibrosis. l ‐cysteine, a known PKM2 inhibitor, blocked these responses and prevented PD‐induced peritoneal fibrosis. These results could provide a novel therapeutic strategy for treating peritoneal fibrosis.
A Radiomic Approach to Clinical MRI Refines the Thalamus-Cognition Link in Multiple Sclerosis
Davis, Levi, Orellana, Renán A., Sun, Rongyi , Özçelik, Sinem , Isenstein, Nina M., Onomichi, Kaho, Iqbal, Rifat, Zhao, B., Zeydan, Burcu , Kantarci, Orhun H. , Jager, Philip L. De , Riley, Claire , De Jager, Philip L , Zeydan, Burcu , Buyukturkoglu, Korhan , Lin, Lu , Davis, Levi, Orellana, Renan E., Iqbal, Rifat, Stern, Yaakov, Riley, Claire

Mayo Clinic

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.05.657698 | PMID 40661563 Get It

Abstract Background and Objectives Radiomics extracts imaging features that may not be detectable through conventional volumetric analyses. Given their role in multiple sclerosis (MS), we applied radiomics to thalamic nuclei and examined their associations with cognitive performance. Methods A total of 601 individuals were included (342 people with MS-PwMS from two cohorts, and 259 healthy controls-HC). Radiomic features (RF) and volumes were extracted from the whole thalamus, five thalamic nuclei, and the putamen segmented on 3D T1-weighted images. Cognitive performance was assessed using the Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) in PwMS, and the Digit Symbol Substitution Test (DSST) in HC. In the first MS cohort, multivariate linear regression in a discovery set (N=103) identified thalamus-derived RF associated with SDMT, which were retested in a replication set (N=63). Their associations with PASAT in a second MS cohort (N=176) and DSST in HC were also evaluated. We then tested whether the same RF, when extracted from the putamen, were associated with SDMT. LASSO models assessed the combined predictive value of RF and volumes. Figure 2 presents an overview of the involvement of different cohorts in the study, outlining the specific study objectives and the statistical analysis approaches employed. Results Twenty-eight RF–ROI pairs were associated with SDMT in the replication set (FDR<0.05). Of these, 24 were also associated with PASAT (FDR≤0.03), and 2 with DSST. Only ventral nuclei volume showed replicated associations among volumetrics. Only 4 putamen-derived pairs were associated with SDMT (FDR=0.04). LASSO results confirmed RF outperformed volumes. Discussion RF extracted from the thalamus are strongly associated with cognitive performance in PwMS, outperforming volumetric measures and supporting their potential as sensitive imaging biomarkers.
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Vannucchi, Alessandro M. , Mascarenhas, John , Bose, Prithviraj , Gale, Robert Peter , Harrison, Claire , Hehlmann, Rüdiger , Koschmieder, Steffen , Tefferi, Ayalew , Barbui, Tiziano , Vannucchi, Alessandro M , Mascarenhas, John , Gale, Robert P , Bose, Prithviraj , Koschmieder, Steffen , Marchetti, Monia , Álvarez‐Larrán, Alberto , Hehlmann, Rűdiger, Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6785954/v1 Get It

Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality-of-life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) taskforce developed a composite endpoint which allows multiple outcomes to be simultaneously measured. The panel used the Desirability-Of-Outcome-Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability-of-Myelofibrosis-Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus and correlations with survival validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requires validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.
Competing Subclones and Fitness Diversity Shape Tumor Evolution Across Cancer Types
Chen, Hai , Shu, Jingmin, Li, Elaine, Wang, Panwen , Bergsagel, Leif, Sun, Zhifu, Zhao, Logan, Bergsagel, P. Leif , Bergsagel, P. Leif , Mudappathi, Rekha , Shi, Changxin, Liu, Li , Chen, Hai, Shu, Jingmin, Bergsagel, L., Sun, Z, Zhao, Logan, Maley, Carlo C.

Mayo Clinic

No container title available | June 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.31.657191 | PMID 40502073 Get It

ABSTRACT Intratumor heterogeneity arises from ongoing somatic evolution complicating cancer diagnosis, prognosis, and treatment. Here we present TEATIME (es t imating e volution a ry events t hrough s i ngle-ti m epoint s e quencing), a novel computational framework that models tumors as mixtures of two competing cell populations: an ancestral clone with baseline fitness and a derived subclone with elevated fitness. Using cross-sectional bulk sequencing data, TEATIME estimates mutation rates, timing of subclone emergence, relative fitness, and number of generations of growth. To quantify intratumor fitness asymmetries, we introduce a novel metric—fitness diversity—which captures the imbalance between competing cell populations and serves as a measure of functional intratumor heterogeneity. Applying TEATIME to 33 tumor types from The Cancer Genome Atlas, we revealed divergent as well as convergent evolutionary patterns. Notably, we found that immune-hot microenvironments constraint subclonal expansion and limit fitness diversity. Moreover, we detected temporal dependencies in mutation acquisition, where early driver mutations in ancestral clones epistatically shape the fitness landscape, predisposing specific subclones to selective advantages. These findings underscore the importance of intratumor competition and tumor-microenvironment interactions in shaping evolutionary trajectories, driving intratumor heterogeneity. Lastly, we demonstrate that TEATIME-derived evolutionary parameters and fitness diversity offer novel prognostic insights across multiple cancer types.